Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib

Jingran Ji, Jonathan W. Riess, Anupam Mitra et al.|Clinical Lung Cancer|2021

Cited by 13